Top Markets
#1 Siren Siren +45.30%
#2 Helium Helium +15.28%
#3 Cryptopia Cryptopia +9.12%
#4 Verus Coin Verus Coin +6.66%
#5 Useless Coin Useless Coin +5.99%
#6 OpenGradient OpenGradient +4.98%
#7 o1.exchange o1.exchange +4.73%
#8 Across Protocol Across Protocol +4.69%
#9 PondCoin PondCoin +4.47%
#10 Mubarak Mubarak +4.45%
Coin of the day
Siren Siren
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Silence Therapeutics plc Silence Therapeutics plc

Silence Therapeutics plc

SLN
Classement en actions #12023
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Prix de l'action
$13.34
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$629.93M
Changement (1 jour)
-0.84%
Changement (1 an)
177.26%
Pays
GB
Échange Silence Therapeutics plc (SLN)

Catégorie

Healthcare
Bénéfices pour Silence Therapeutics plc (SLN)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Silence Therapeutics plc, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Silence Therapeutics plc de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH